Drug Profile

ABBV 787

Alternative Names: ABBV-787; anti-CD33 ADC ABBV-787

Latest Information Update: 21 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AbbVie
Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
Mechanism of Action Bromodomain and extraterminal domain protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Feb 2025 AbbVie terminates phase I trial in Acute myeloid leukaemia (Second-line therapy or greater) in USA, South Korea, Japan, Israel, Australia due to strategic considerations (IV) (NCT06068868)
13 Nov 2023 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in South Korea, Japan, Israel, Australia (IV) (NCT06068868)
13 Nov 2023 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT06068868)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com